Source:http://linkedlifedata.com/resource/pubmed/id/17954265
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
2007-10-23
|
| pubmed:abstractText |
Medulloblastoma is a malignant invasive embryonal tumor, occurring in children mainly. It is rare in adults (<1% of adult brain tumors), and so comprehensive cytogenetic and molecular biological data on adult medulloblastomas are very limited. Conventional therapies provide disappointing long-term disease control, and new therapeutic options are being tested. We performed comprehensive cytogenetic analyses of an adult medulloblastoma, WHO grade IV, using trypsin-Giemsa staining (GTG-banding), multicolor fluorescence in situ hybridization (M-FISH), and locus-specific FISH, complemented by molecular karyotyping using high-density single nucleotide polymorphism (SNP) arrays. GTG-banding of 25 metaphases revealed 31 structural chromosomal aberrations, predominantly located on chromosomes 4q, 9q, 10q, 11p, and 20q, which were confirmed by M-FISH. Two novel, so far not described translocations were found: t(4;11)(q25;p15) and t(9;20)(p23;p12). GTG-banding, locus-specific FISH, and M-FISH detected numerical changes of chromosomes 8, 14, 18, 19, 20, 21, and 22. Molecular karyotyping by SNP array confirmed chromosomal changes -2p, -10q, -16q, and -Xq and revealed de novo partial uniparental disomy 1q and 9q. Applying an upcoming therapeutic approach, we found that primary medulloblastoma cells were resistant to TRAIL, a novel anticancer cytokine, but could be efficiently sensitized by cotreatment with the proteasome inhibitor bortezomib. Bortezomib-TRAIL cotreatment may serve as a powerful therapeutic option for medulloblastoma patients.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Oct
|
| pubmed:issn |
0165-4608
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
15
|
| pubmed:volume |
178
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
104-13
|
| pubmed:meshHeading |
pubmed-meshheading:17954265-Adult,
pubmed-meshheading:17954265-Cerebellar Neoplasms,
pubmed-meshheading:17954265-Child,
pubmed-meshheading:17954265-Chromosome Aberrations,
pubmed-meshheading:17954265-Chromosome Banding,
pubmed-meshheading:17954265-Female,
pubmed-meshheading:17954265-Flow Cytometry,
pubmed-meshheading:17954265-Gene Expression Profiling,
pubmed-meshheading:17954265-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:17954265-Humans,
pubmed-meshheading:17954265-In Situ Hybridization, Fluorescence,
pubmed-meshheading:17954265-Karyotyping,
pubmed-meshheading:17954265-Matrix Metalloproteinase 2,
pubmed-meshheading:17954265-Medulloblastoma,
pubmed-meshheading:17954265-Phosphopyruvate Hydratase,
pubmed-meshheading:17954265-Polymorphism, Single Nucleotide,
pubmed-meshheading:17954265-Synaptophysin
|
| pubmed:year |
2007
|
| pubmed:articleTitle |
Cytogenetic and molecular biological characterization of an adult medulloblastoma.
|
| pubmed:affiliation |
Biotechnical-Biomedical Center (BBZ) and Institute of Clinical Immunology and Transfusion Medicine, Faculty of Medicine, University of Leipzig, Leipzig, Germany. heidrun.holland@medizin.uni-leipzig.de
|
| pubmed:publicationType |
Journal Article,
Case Reports
|